Conduit Pharmaceuticals Inc. (CDT) - Total Assets
Based on the latest financial reports, Conduit Pharmaceuticals Inc. (CDT) holds total assets worth $3.46 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Conduit Pharmaceuticals Inc. reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Conduit Pharmaceuticals Inc. - Total Assets Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s total assets have evolved over time, based on quarterly financial data. Check CDT cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Conduit Pharmaceuticals Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Conduit Pharmaceuticals Inc.'s total assets of $3.46 Billion consist of 38.1% current assets and 61.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.0% |
| Accounts Receivable | $462.85 Million | 13.1% |
| Inventory | $402.35 Million | 11.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $399.80 Million | 11.3% |
| Goodwill | $1.04 Billion | 29.3% |
Asset Composition Trend (2021–2025)
This chart illustrates how Conduit Pharmaceuticals Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CDT company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Conduit Pharmaceuticals Inc.'s current assets represent 38.1% of total assets in 2025, a decrease from 48.9% in 2021.
- Cash Position: Cash and equivalents constituted 11.0% of total assets in 2025, down from 22.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 40.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 29.3% of total assets.
Conduit Pharmaceuticals Inc. Competitors by Total Assets
Key competitors of Conduit Pharmaceuticals Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Conduit Pharmaceuticals Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.09 | 1.31 | 0.54 |
| Quick Ratio | 1.40 | -80.72 | 0.54 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $666.25 Million | $1.40 Million | $-88.34K |
Conduit Pharmaceuticals Inc. - Advanced Valuation Insights
This section examines the relationship between Conduit Pharmaceuticals Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.16 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 84412.8% |
| Total Assets | $3.54 Billion |
| Market Capitalization | $3.37 Million USD |
Valuation Analysis
Below Book Valuation: The market values Conduit Pharmaceuticals Inc.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Conduit Pharmaceuticals Inc.'s assets grew by 84412.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Conduit Pharmaceuticals Inc. (2021–2025)
The table below shows the annual total assets of Conduit Pharmaceuticals Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.54 Billion | +84412.78% |
| 2024-12-31 | $4.19 Million | -41.96% |
| 2023-12-31 | $7.22 Million | +144380.00% |
| 2022-12-31 | $5.00K | -97.65% |
| 2021-12-31 | $213.12K | -- |
About Conduit Pharmaceuticals Inc.
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the tre… Read more